Featured Research

from universities, journals, and other organizations

Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield

Date:
June 24, 2009
Source:
Empa
Summary:
Vaccinations are the most effective weapons in the fight against infectious diseases. However, developing novel vaccines alone is not sufficient to win the battle and the development and manufacture of economically priced vaccines in sufficient quantities represent real research challenges. Swiss researchers have developed a new bioprocess which increases the vaccine yield by a factor of fifty compared to conventional techniques.

Empa researchers have successfully scaled-up a new method of producing vaccines to enable the use of a bioreactor.
Credit: Image courtesy of Empa

Empa researchers have managed to adapt a process for manufacturing certain vaccines – in particular that against Haemophilus influenae bacteria – for use in bioreactors, with the result that the yield is enhanced enormously. Haemophilus influenzae not only causes serious infection in the nose and throat, but can result in potentially fatal meningitis. The Swiss Federal Vaccination Commission therefore strongly recommends that children be vaccinated against this organism.

Related Articles


So-called conjugate vaccines have proven to be especially safe and effective in this respect. In this technique, antigens in the form of sugar chains (oligosaccharides) are chemically linked to carrier proteins in a complex process known as glycosylation.

Designer bacteria instead of chemical processes

A more elegant way, however, is to allow this task to be performed by specially designed, non-toxic Escherichia coli bacteria, which are normally present in the human gut. For this purpose GlycoVaxyn has developed an enzyme-based in vivo method. The Escherichia coli bacteria were genetically modified, so that they glycosylate certain proteins – in order words, they generate vaccine material. Unfortunately, however, the yield in the GlycoVaxyn process was too low. The vaccine manufacturer needed the help of specialists to upscale their process so it could be used in bioreactors. Their search came to an end in Empa’s Biomaterials laboratory, where both the necessary know-how and the bioreactors were at hand.

From cell culture to bioreactor

“This is a classic biotechnology 'scale-up-problem'. It is not simply a question of multiplying everything by a hundred,” explains Empa expert Julian Ihssen. ”On a large scale everything becomes more difficult. At higher cell densities many factors change.” For example, Escherichia coli bacteria begin to produce acetic acid. The oxygen supply is also no longer optimal. This makes the results very difficult to predict.

The Empa researchers discovered that the production of the glycoconjugate, i.e. the vaccine itself, was influenced by both the type of culture medium used as well as the way the process steps were controlled. Several different process sequences were tried out, with the best turning out to be a «fed-batch» strategy involving the periodic addition of glycerol as the main nutrient.

A significantly higher vaccine yield

The novel bioprocess resulted in a forty times increase in the biomass concentration – that is, the bacterial cell density – compared to the previously employed shaken flask technique. At the same time each individual bacteria produced on average somewhat more vaccine than before, so that all told the yield in purified conjugated vaccine rose from 0.6 to over 30 milligrams per liter of culture medium, an increase of about a factor fifty. “The results using a three liter bioreactor were very promising. Now we are hoping to be able to scale up the principle even more to the industry standard level,” says GlycoVaxyn co-founder Michael Wacker.

The same process can very likely also be used to manufacture other conjugated vaccines too, for instance against certain diarrhea producing organisms, or salmonella. This would above all offer a glimmer of hope to developing countries, where often vaccination campaigns fail because of the high price of vaccines.


Story Source:

The above story is based on materials provided by Empa. Note: Materials may be edited for content and length.


Cite This Page:

Empa. "Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield." ScienceDaily. ScienceDaily, 24 June 2009. <www.sciencedaily.com/releases/2009/06/090612122455.htm>.
Empa. (2009, June 24). Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2009/06/090612122455.htm
Empa. "Vaccines From The Bioreactor: Bioprocess Increases Vaccine Yield." ScienceDaily. www.sciencedaily.com/releases/2009/06/090612122455.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Just A Half-Hour Of Lost Sleep Could Lead To Weight Gain

Just A Half-Hour Of Lost Sleep Could Lead To Weight Gain

Newsy (Mar. 6, 2015) — A new study found losing just half an hour of sleep could make you gain weight. Video provided by Newsy
Powered by NewsLook.com
Suicide Rates Up For Young Women In U.S.

Suicide Rates Up For Young Women In U.S.

Newsy (Mar. 6, 2015) — According to a report from the CDC, suicide rates among young women increased from 1994 to 2012 while rates among young men have decreased. Video provided by Newsy
Powered by NewsLook.com
Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) — Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins